Biocon Q4 Results: Net profit down 57% at Rs 198.6 crore
Biocon Ltd. reported a significant decline in its Q4 FY26 net profit, falling 56.8% to ₹198.6 crore, primarily due to an ₹80.4 crore exceptional item. Despite the profit drop, the company's consolidated revenue for the quarter increased to ₹4516.6 crore. For the full fiscal year 2026, net profit also decreased to ₹368.8 crore, while revenue grew to ₹16927 crore.
May 08 2026 10:05:00
Biocon Ltd - 532523 - Announcement under Regulation 30 (LODR)-Monitoring Agency Report
Biocon's monitoring agency report confirms full utilization of over Rs.8,650 crore QIP funds as per stated objects for Q4 FY26. The funds were primarily used for acquisitions and debt repayment across two QIPs.
May 08 2026 00:05:00
Biocon Ltd - 532523 - Outcome Of Board Meeting_Change In Long Term Incentive Plan
Biocon's Board approved the acquisition of the remaining ~2% equity shares in its material subsidiary, Biocon Biologics Limited (BBL). This acquisition, valued at Rs.330.73 crores through a preferential issue of Biocon shares, aims for full integration and operational synergies, making BBL a nearly 99.99% owned subsidiary.
May 07 2026 23:05:00
Biocon Ltd - 532523 - Announcement under Regulation 30 (LODR)-Issue of Securities
Biocon's Board approved a preferential issue of 87.92 lakh equity shares at Rs. 376.16 per share, totaling Rs. 330.73 crore. This issuance is to acquire the remaining ~2% stake in its material subsidiary, Biocon Biologics Limited (BBL), aiming for full integration and simplified corporate structure.
May 07 2026 23:05:00
Biocon Ltd - 532523 - Announcement under Regulation 30 (LODR)-Acquisition
Biocon plans to acquire the remaining ~2% equity stake in its material subsidiary, Biocon Biologics. The acquisition, valued at Rs. 330.73 crores through a preferential issue of Biocon shares, will increase its ownership to approximately 99.99%, aiming to fully integrate the biosimilars business.
May 07 2026 23:05:00
Biocon Ltd - 532523 - Outcome Of Board Meeting_Completion Of Tenure Of Statutory Auditors
Biocon's Board approved the acquisition of the remaining ~2% equity shares in its material subsidiary, Biocon Biologics Limited (BBL). This acquisition, valued at Rs.330.73 crores through a preferential issue of Biocon shares, aims for full integration and operational synergies, making BBL a nearly 99.99% owned subsidiary.
May 07 2026 23:05:00
Biocon Ltd - 532523 - Announcement under Regulation 30 (LODR)-Change in Directorate
Biocon's Board has appointed six new Directors, comprising five Independent Directors and one Non-Executive Non-Independent Director. These appointments are effective from August 01, 2026, and are subject to shareholder approval.
May 07 2026 23:05:00
Biocon Ltd - 532523 - Announcement under Regulation 30 (LODR)-Change in Management
Biocon's board approved the appointment of six new directors, comprising five independent directors and one non-executive non-independent director. These appointments are effective August 1, 2026, and are subject to shareholder approval through postal ballot.
May 07 2026 23:05:00
Biocon Ltd - 532523 - Fixation Of Record Date For Dividend
Biocon Limited has set July 3, 2026, as the record date for its final dividend. Eligible shareholders will receive ₹0.50 per equity share for FY26.
May 07 2026 23:05:00
Biocon Ltd - 532523 - Corporate Action-Board approves Dividend
Biocon's Board recommended a final dividend of ₹0.50 per share for FY26, equivalent to 10% of the ₹5 face value. Payment is scheduled by August 31, 2026, subject to shareholder approval.
May 07 2026 23:05:00
Read More